Purpose

To describe new users of atypical antipsychotics (APs) in terms of sociodemographic characteristics, cardio-metabolic risk profile, prescription patterns, healthcare costs and cardio-metabolic events over the 24 months after treatment initiation.

Methods

Atypical AP new users were selected from the ReS database and grouped into three: patients already affected by cardio-metabolic diseases (group A), patients without these clinical conditions but with predisposing conditions (group B) and patients without cardio-metabolic diseases and predisposing conditions (group C). Annual prescription patterns and healthcare costs were analysed. Subjects of groups B and C were matched with controls to compare the occurrences of cardio-metabolic events over 24 months.

Results

Thirty-two thousand thirty-four new users of atypical APs were selected (median age 69). The 22.3% had cardio-metabolic diseases, 14.8% had predisposing conditions and 62.9% had none of these. The 99.3% received monotherapy. The mean annual cost per patient was €2785, and the median cost was €1108. After 24 months, a cardio-metabolic event occurred in 11.5% of group B vs. 8.7% of the controls (p < .01), and in 5.0% of group C vs. 2.1% of the controls (p < .01).

Conclusion

Patients treated with atypical AP were on average old and, in a non-negligible amount, with cardio-metabolic disease or predisposing conditions. New users of atypical APs showed a significantly higher likelihood to develop a cardio-metabolic event early after treatment initiation.

中文翻译：

---

有关非典型抗精神病药新用户的真实数据：来自大型意大利数据库的特征，处方模式，医疗保健费用和早期心脏代谢事件。

目的

在治疗开始后的24个月内，根据社会人口统计学特征，心血管代谢风险特征，处方模式，医疗保健费用和心血管代谢事件来描述非典型抗精神病药（AP）的新用户。

方法

从ReS数据库中选择非典型AP新用户，并将其分为三类：已经受到心脏代谢疾病影响的患者（A组），没有这些临床症状但有易患疾病的患者（B组）和没有心脏代谢疾病且有易患疾病的患者条件（C组）。分析了年度处方模式和医疗费用。将B和C组的受试者与对照组进行比较，以比较24个月内心脏代谢事件的发生率。

结果

选择了3.24万名非典型AP的新用户（中位年龄为69岁）。22.3％的人患有心脏代谢疾病，14.8％的人患有诱发疾病，62.9％的人没有这些疾病。99.3％接受了单药治疗。每位患者的平均年度费用为2785欧元，中位数费用为1108欧元。24个月后，B组的心脏代谢事件发生率为11.5％，对照组为8.7％（p  <.01），C组的心脏代谢事件为5.0％，而对照组为2.1％（p  <.01） 。

结论

使用非典型AP治疗的患者平均年龄大，且心血管疾病或易感疾病的数量不可忽略。非典型AP的新使用者显示出在治疗开始后早期发生心脏代谢事件的可能性大大提高。